NASDAQ: COO · Medical Instruments & Supplies
Cooper Companies (COO) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Cooper Companies (COO) at $70.88 a share. The stock last closed at $61.88, which puts the model's fair value 14.5% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. The Cooper Companies, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 held the fair value at $70.88, within 1% of the run of 7 Nov 2026.
What the model makes of itThe price of $61.88 is 14.5% below it: Fairly valued, on a high evidence grade.
What's nextReports on 3 Dec 2026. Options prices imply a move of about 14% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give COO?
The calibrated range for COO over 63 trading days is $53.00 to $72.82. It sits around the last close, and its width comes from the volatility that COO's own options imply (47% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $58.03 to $84.97. In 69% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
The Cooper Companies, Inc. (COO) is a global medical device firm. It develops, produces and distributes products through two business units, CooperVision and CooperSurgical, and CooperVision specialises in contact lenses.
Faircurve's model put the fair value at $70.88 a share on 14 Nov 2026. That is the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $70.57, so the fair value moved +0.4%. The calibrated range over 63 trading days is $53.66 to $73.72. It is built around the price from the volatility the stock's own options imply, and calibrated weekly against realised prices, using 8,038 past valuations, refreshed 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence High. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
The model's overall quality score is 55 out of 100, a composite of six factors scored against comparable companies. Stability stands out at 100, with five-year EBITDA margin downside volatility of 0.9 pts against a peer median of 1.9 pts. Profitability scores 68, with ROIC of 5.1% against a peer median of 3.3%. The model compares the company with Repligen Corporation, Baxter International, Avantor, Solventum, AptarGroup, Teleflex, Merit Medical Systems and West Pharmaceutical Services.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does COO report earnings, and how has the stock reacted?
Cooper Companies's next earnings report is scheduled for 3 Dec 2026. Companies can move their dates.
On 16 Nov 2026, COO's 30 day implied volatility worked out to a move of about 13.6% over one month, in either direction. That is a size, not a direction.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across COO's last 8 reports, ignoring direction, was 9.4%.
What the options market has priced for a month's move in COO
How does COO score on business quality?
Cooper Companies's overall quality score is 55 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 68 | 5.1%ROIC | 3.3% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 52 | 1.19xFCF / net income | 1.42x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 36 | 5.1%Revenue growth, trailing | 5.7% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 38 | 0.5%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 38 | 2.62xNet debt / EBITDA | 1.49x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 100 | 0.9 ptsEBITDA margin downside volatility, 5y | 1.9 pts |
How does COO compare with similar companies?
The companies in medical instruments & supplies closest to Cooper Companies in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| RGEN Repligen Corporation | $162.78 | $152.66 | -6.2% | Fairly valued |
| BAX Baxter International Inc. | $25.54 | $24.84 | -2.7% | Fairly valued |
| AVTR Avantor, Inc. | $15.32 | $20.70 | +35.1% | Undervalued |
| SOLV Solventum Corporation | $88.65 | $88.47 | -0.2% | Fairly valued |
| ATR AptarGroup, Inc. | $143.17 | $137.10 | -4.2% | Fairly valued |
| TFX Teleflex Incorporated | $157.10 | $169.00 | +7.6% | Fairly valued |
| MMSI Merit Medical Systems, Inc. | $86.35 | $82.63 | -4.3% | Fairly valued |
| WST West Pharmaceutical Services, Inc. | $417.80 | $372.00 | -11.0% | Fairly valued |
What the comparable companies' multiples alone would give for COO, the peer-implied price, is $80.81 a share on this run. The fair value weighs that against the company's own multiple.
All medical instruments & supplies stocks ranked by gap to fair value
Cooper Companies at a glance
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses.
- Market value
- $11.9B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Revenue expected, next twelve months
- $4.4B
- Consensus revenue growth, next fiscal year
- +3.6%
- Analysts with estimates
- 11
- Beta to the US market
- 0.36
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. COO was among them.
How the fair value is worked out: the model prices Cooper Companies on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for COO was $70.57. As of 14 Nov 2026 it is $70.88, a change of +0.4%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Cooper Companies's valuation
Is Cooper Companies stock undervalued or overvalued?
On Faircurve's model, COO reads as Fairly valued as of 14 Nov 2026. The model's fair value is $70.88 a share against a last close of $61.88, a gap of +14.5%.
What is COO's fair value?
$70.88 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $58.03 to $84.97.
What price range does the model give COO?
$53.00 to $72.82 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Cooper Companies report earnings next?
The next report is scheduled for 3 Dec 2026. Companies can move their dates.
How much has COO moved on past earnings reports?
Across its last 8 reports the median two session move was 9.4%, ignoring direction. The largest was -20.0% around the report of 9 Sep 2026.
How confident is the model in this valuation?
The model's evidence grade for COO is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on COO
The model holds no idea open on COO today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on COO with their outcomes. A free account is enough.